目的 探讨复方苁蓉益智胶囊联合重酒石酸卡巴拉汀胶囊治疗阿尔茨海默病的临床疗效。方法 选取2014年1月-2017年1月在文昌市人民医院治疗的阿尔茨海默病患者98例为研究对象，将入组患者随机分为对照组（49例）和治疗组（49例）。对照组口服重酒石酸卡巴拉汀胶囊，起始剂量为1.5 mg/次，2次/d，连用4周后若对该剂量耐受良好，增至3.0 mg/次，2次/d，继续连用4周后对该剂量耐受良好，可增至6.0 mg/次，2次/d。治疗组在对照组治疗的基础上口服复方苁蓉益智胶囊，1.2 g/次，3次/d。两组均持续治疗6个月。观察两组患者的临床疗效，比较治疗前后两组患者简易智力状态检查量表（MMSE）评分、阿尔兹海默病评定量表-认知（ADAS-Cog）评分、阿尔茨海默病行为病理评定量表（BEHAVE-AD）评分、日常生活能力量表（ADL）评分和血清学指标。结果 治疗后，对照组和治疗组临床总有效率分别为81.63%和95.92%，两组比较差异有统计学意义（P<0.05）。治疗后，两组MMSE评分、ADL评分均明显升高，ADAS-Cog评分、BEHAVE-AD评分均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组相关评分显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清IL-6、Aβ、IL-1β、BK水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组血清学指标水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 复方苁蓉益智胶囊联合重酒石酸卡巴拉汀胶囊治疗阿尔茨海默病具有较好的临床疗效，可有效提高患者认知功能和日常生活能力，降低炎性因子水平，具有一定临床推广应用价值。

Objective To explore the clinical effects of Compound Congrong Yizhi Capsules combined with Rivastigmine Hydrogen Tartrate Capsules in treatment of Alzheimer's disease. Methods Patients (98 cases) with Alzheimer's disease in Wenchang City People's Hospital from January 2014 to January 2017 were randomly divided into control (49 cases) and treatment (49 cases) groups. Patients in the control group were po administered with Rivastigmine Hydrogen Tartrate Capsules with starting dosage 1.5 mg/time, twice daily, and the dosage was increased to 3.0 mg/time, twice daily after 4 weeks, if the dose was well tolerated. And then the dosage was increased to 6.0 mg/time, twice daily after 4 weeks, if the dose was well tolerated. Patients in the treatment group were po administered with Compound Congrong Yizhi Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the MMSE score, ADAS-Cog score, BEHAVE-AD score, ADL score, and the serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.63% and 95.92%, respectively, and there was difference between two groups (P < 0.05). After treatment, MMSE score and ADL score in two groups were significantly increased, but ADAS-Cog score and BEHAVE-AD score in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the related scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, IL-6, Aβ, IL-1β, and BK levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05).Conclusion Compound Congrong Yizhi Capsules combined with Rivastigmine Hydrogen Tartrate Capsules has clinical curative effect in treatment of Alzheimer's disease, can effectively improve patient's cognitive function and daily life ability, reduce the levels of inflammatory factors, which has a certain clinical application value.